Welcome to Paid Research Studies.


Browse Locations ... United Kingdom» ... Northern Ireland






  • Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations

    Condition:   Smoking Cessation
    Interventions:   Drug: Nicotine (2 mg);   Drug: Nicotine (4 mg)
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified May 2013
  • Myeloproliferative Neoplasms: an In-depth Case-control Study

    Conditions:   Polycythemia Vera;   Essential Thrombocythemia;   Primary Myelofibrosis
    Interventions:   Other: Methodological pens;   Other: Methodological compensation;   Other: Methodological trolley tokens
    Sponsors:   Queen's University, Belfast;   Queen's University, Belfast;   University Hospital Southampton NHS Foundation Trust.;   University of Manchester;   Western Australian Institute for Medical Research;   Mayo Clinic
    Recruiting - verified April 2013
  • A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

    Condition:   Asthma
    Interventions:   Drug: Symbicort pMDI;   Drug: Symbicort pMDI;   Drug: budesonide pMDI;   Drug: budesonide pMDI
    Sponsors:   AstraZeneca;   AstraZeneca
    Recruiting - verified May 2013
  • Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

    Conditions:   Coronary Artery Disease;   Angina Pectoris
    Interventions:   Drug: Ranolazine;   Drug: Placebo
    Sponsors:   Gilead Sciences;   Gilead Sciences
    Recruiting - verified May 2013
  • Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

    Conditions:   Cardiovascular Disease;   Diabetes Mellitus, Type 2
    Interventions:   Drug: Dulaglutide;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2013
  • This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

    Condition:   Heart Failure With Reduced Ejection Fraction
    Interventions:   Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified April 2013
  • Strategic Timing of Antiretroviral Treatment

    Condition:   HIV Infection
    Intervention:   Drug: All licensed antiretroviral medications
    Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID);   Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark;   Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom;   The Kirby Institute for Infection and Immunity in Society;   The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA;   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   German Federal Ministry of Education and Research;   NEAT - European AIDS Treatment Network;   National Health and Medical Research Council, Australia;   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Mental Health (NIMH);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   Abbott;   Bristol-Myers Squibb;   Gilead Sciences;   GlaxoSmithKline;   Merck;   Tibotec Pharmaceutical Limited
    Recruiting - verified May 2013
Main Menu
Clinical Trial Locations
Clinical Trial Categories